泌尿生殖器治療薬市場- 世界の産業規模、シェア、動向、機会、予測、適応症別、製品別、地域別セグメント、競合、2020年～2030年

世界の泌尿生殖器治療薬市場は、2024年に278億米ドルと評価され、2030年までの年間平均成長率（CAGR）は2.53%で、予測期間を通じて大幅な成長が予測されています。

泌尿生殖器」（Genitourinary：GU）という用語は、生殖器と泌尿生殖器の両方を含む複合システムを指し、様々な身体機能において重要な役割を果たしています。生殖器（性器）は、男性の陰茎、精巣、精巣上体、精管、前立腺、精嚢、女性の外陰部、膣、子宮頸部、子宮体部、卵管、卵巣を含む性機能および生殖機能を担っています。泌尿器は老廃物を尿として排出する器官で、腎臓、尿管、膀胱、尿道が含まれます。

世界人口の高齢化に伴い、前立腺疾患、尿失禁、腎臓疾患などの泌尿生殖器疾患の有病率が上昇し、泌尿生殖器治療薬の需要を牽引しています。例えば、世界保健機関（WHO）が2022年3月に発表した報告書によると、15歳から49歳までの単純ヘルペスウイルス2型（HSV-2）に感染している人は世界で年間4億9,100万人に上り、この年齢層の世界人口の約13％が感染していることが明らかになりました。HSV-2は性行為によって感染し、生涯にわたって痛みを伴う性器のただれを引き起こし、HIVのような他の疾患への感受性を高める可能性があります。このように広く蔓延していることから、認知度の向上、予防、効果的な治療ソリューションの必要性が強調されています。

主な市場促進要因

医薬品開発の進歩

主な市場課題：

ジェネリック医薬品の競合

主な市場動向：

泌尿器がん治療薬の増加

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の泌尿生殖器治療薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別（前立腺がん、卵巣がん、膀胱がん、子宮頸がん、腎臓がん、勃起不全、尿路感染症、尿失禁および過活動膀胱、性感染症、間質性膀胱炎、血尿、前立腺肥大症）
  • 製品別（ホルモン療法、婦人科、泌尿器科、抗感染薬、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の泌尿生殖器治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の泌尿生殖器治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の泌尿生殖器治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の泌尿生殖器治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの泌尿生殖器治療薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の泌尿生殖器治療薬市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Abbott Laboratories Ltd.
• Bristol-Myers Squibb Co.
• Novartis AG
• Genentech, Inc.
• F. Hoffmann-La Rochel Ltd.
• Ionis Pharmaceuticals, Inc.
• Eli Lilly and Company
• Merck & Co, Inc.
• Pfizer, Inc.
• AstraZeneca Plc.

第17章 戦略的提言

第18章 調査会社について・免責事項

The global Genitourinary Drugs Market was valued at USD 27.80 billion in 2024 and is projected to experience substantial growth throughout the forecast period, with a compound annual growth rate (CAGR) of 2.53% through 2030. The term "genitourinary" (GU) refers to the combined system involving both the genital and urinary organs, which play vital roles in various bodily functions. The genital organs (genitalia) are responsible for sexual and reproductive functions, including the penis, testes, epididymis, vas deferens, prostate gland, and seminal vesicles in males, and the vulva, vagina, cervix, uterus, fallopian tubes, and ovaries in females. The urinary organs facilitate the elimination of waste products in the form of urine, encompassing the kidneys, ureters, bladder, and urethra.

With the aging global population, the prevalence of genitourinary disorders-such as prostate issues, urinary incontinence, and kidney diseases-has risen, driving the demand for genitourinary drugs. For instance, a report by the World Health Organization (WHO) from March 2022 revealed that 491 million people worldwide, aged 15 to 49, are infected with herpes simplex virus type 2 (HSV-2) annually, affecting approximately 13% of the global population in this age group. HSV-2 is a highly prevalent sexually transmitted infection that can result in lifelong infection, causing painful genital sores and increasing susceptibility to other conditions like HIV. This widespread prevalence emphasizes the need for greater awareness, prevention, and effective treatment solutions.

Key Market Drivers:

Advancements in Drug Development

Immunotherapy has emerged as a transformative approach for treating genitourinary cancers, such as renal cell carcinoma and urothelial carcinoma. Immune checkpoint inhibitors, including PD-1 and PD-L1 inhibitors, stimulate the patient's immune system to target and destroy cancer cells. Targeted therapies have shown success in treating genitourinary cancers by blocking specific molecular pathways or receptors involved in tumor growth. For example, tyrosine kinase inhibitors (TKIs) have demonstrated effectiveness in treating renal cell carcinoma.

Further advancements in genomics and molecular biology allow for more precise drug development in the genitourinary space, identifying specific genetic mutations or biomarkers to tailor treatments to an individual's genetic profile. Antibody-Drug Conjugates (ADCs), which deliver cytotoxic agents directly to cancer cells while minimizing damage to healthy tissue, are being developed for urothelial carcinoma and other cancers. The National Institutes of Health (NIH) highlighted the advancements in urothelial carcinoma treatments at the 2023 ASCO-GU Cancers Symposium, underscoring the need for improved treatment strategies as this cancer remains a leading cause of mortality. Hormonal therapies for conditions like prostate cancer are evolving with the introduction of more effective agents that block androgen receptors or reduce testosterone levels. Additionally, combinations of chemotherapy, immunotherapy, and radiation therapy are being explored to enhance treatment outcomes while reducing side effects. For genitourinary infections, the development of next-generation antibiotics with better resistance profiles and fewer side effects is increasingly important due to the growing challenge of antibiotic resistance. Biologic drugs, such as monoclonal antibodies, are also being developed for a range of genitourinary conditions, offering the potential to target specific proteins or immune cells involved in disease progression.

Key Market Challenges:

Generic Competition

As patents for branded genitourinary drugs expire, generic pharmaceutical companies often introduce lower-cost alternatives, leading to significant market competition. This can decrease the market share and profitability of the original drugs, resulting in price reductions. With multiple generic manufacturers entering the market, prices for these generic versions typically decline, which impacts the revenue of the original drug. Branded drugs may experience a rapid decline in market share upon the introduction of generics, which is especially challenging for pharmaceutical companies that rely on a small number of blockbuster genitourinary drugs for revenue. The revenue generated by these blockbuster drugs often funds ongoing research and development efforts for new treatments. When generic competition erodes these revenues, it can hinder a company's ability to invest in innovative drug development. The influx of generics can saturate the market, making it challenging for any single manufacturer to capture a substantial market share. This may lead to price wars and reduced profitability for generic producers. Although generics tend to be more cost-effective, patients and physicians may still favor branded drugs due to perceived efficacy, safety, or familiarity. However, cost considerations may influence patient and physician preferences toward generics.

Key Market Trends:

Rise in Urologic Cancer Therapies

The emergence of targeted therapies has revolutionized the treatment of urologic cancers. Drugs designed to target specific molecular pathways and genetic mutations driving cancer growth have improved the effectiveness of treatments while reducing side effects. Immunotherapies, such as immune checkpoint inhibitors, have shown promising results in treating urologic cancers, particularly renal cell carcinoma and urothelial carcinoma, by enhancing the immune system's ability to target and destroy cancer cells. The combination of immunotherapy, targeted therapies, and traditional chemotherapy has become a standard treatment approach, aiming to maximize treatment efficacy and improve patient outcomes.

Advancements in genomics and molecular diagnostics have enabled personalized treatment approaches, allowing oncologists to tailor urologic cancer therapies to a patient's genetic profile for more effective and targeted treatments. Enhanced screening and diagnostic methods, such as PSA testing for prostate cancer and advanced imaging techniques, have led to earlier detection of urologic cancers, which often results in better treatment outcomes. The pharmaceutical industry continues to invest in the development of novel urologic cancer drugs, expanding the drug pipeline and providing additional treatment options for both patients and healthcare providers.

Key Market Players:

• Abbott Laboratories Ltd.
• Bristol-Myers Squibb Co.
• Novartis AG
• Genentech, Inc.
• F. Hoffmann-La Roche Ltd.
• Ionis Pharmaceuticals, Inc.
• Eli Lilly and Company
• Merck & Co., Inc.
• Pfizer, Inc.
• AstraZeneca Plc.

Report Scope:

This report segments the global genitourinary drugs market into the following categories and provides an in-depth analysis of industry trends:

By Indication:

• Prostate Cancer
• Ovarian Cancer
• Bladder Cancer
• Cervical Cancer
• Renal Cancer
• Erectile Dysfunction
• Urinary Tract Infections
• Urinary Incontinence & Overactive Bladder
• Sexually Transmitted Diseases, Interstitial Cystitis
• Hematuria
• Benign Prostatic Hyperplasia

By Product:

• Hormonal Therapy
• Gynecological Drugs
• Urological Drugs
• Anti-infectives
• Others

By Region:

• North America: United States, Canada, Mexico
• Asia-Pacific: China, India, South Korea, Australia, Japan
• Europe: Germany, France, United Kingdom, Spain, Italy
• South America: Brazil, Argentina, Colombia
• Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

The report provides detailed company profiles and analyses of key players in the global genitourinary drugs market.

Available Customizations:

TechSci Research offers customization options for this market report, including a detailed analysis and profiling of additional market players (up to five), tailored to the specific needs of a company.

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Genitourinary Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence & Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis, Hematuria, Benign Prostatic Hyperplasia)
  • 5.2.2. By Product (Hormonal Therapy, Gynecological, Urologicals, Anti-infectives, others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Genitourinary Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Product
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Genitourinary Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Product
  • 6.3.2. India Genitourinary Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Product
  • 6.3.3. Australia Genitourinary Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Product
  • 6.3.4. Japan Genitourinary Drugs Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Indication
      • 6.3.4.2.2. By Product
  • 6.3.5. South Korea Genitourinary Drugs Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Indication
      • 6.3.5.2.2. By Product

7. Europe Genitourinary Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Product
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Genitourinary Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Product
  • 7.3.2. Germany Genitourinary Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Product
  • 7.3.3. Spain Genitourinary Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Product
  • 7.3.4. Italy Genitourinary Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Product
  • 7.3.5. United Kingdom Genitourinary Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Product

8. North America Genitourinary Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Product
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Genitourinary Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Product
  • 8.3.2. Mexico Genitourinary Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Product
  • 8.3.3. Canada Genitourinary Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Product

9. South America Genitourinary Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Product
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Genitourinary Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Product
  • 9.3.2. Argentina Genitourinary Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Product
  • 9.3.3. Colombia Genitourinary Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Product

10. Middle East and Africa Genitourinary Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Product
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Genitourinary Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Product
  • 10.3.2. Saudi Arabia Genitourinary Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Product
  • 10.3.3. UAE Genitourinary Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Product

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Genitourinary Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Abbott Laboratories Ltd.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bristol-Myers Squibb Co.
  • 16.2.1. Business Overview
  • 16.2.2. Company Snapshot
  • 16.2.3. Products & Services
  • 16.2.4. Financials (In case of listed companies)
  • 16.2.5. Recent Developments
  • 16.2.6. SWOT Analysis
• 16.3. Novartis AG
  • 16.3.1. Business Overview
  • 16.3.2. Company Snapshot
  • 16.3.3. Products & Services
  • 16.3.4. Financials (In case of listed companies)
  • 16.3.5. Recent Developments
  • 16.3.6. SWOT Analysis
• 16.4. Genentech, Inc.
  • 16.4.1. Business Overview
  • 16.4.2. Company Snapshot
  • 16.4.3. Products & Services
  • 16.4.4. Financials (In case of listed companies)
  • 16.4.5. Recent Developments
  • 16.4.6. SWOT Analysis
• 16.5. F. Hoffmann-La Rochel Ltd.
  • 16.5.1. Business Overview
  • 16.5.2. Company Snapshot
  • 16.5.3. Products & Services
  • 16.5.4. Financials (In case of listed companies)
  • 16.5.5. Recent Developments
  • 16.5.6. SWOT Analysis
• 16.6. Ionis Pharmaceuticals, Inc.
  • 16.6.1. Business Overview
  • 16.6.2. Company Snapshot
  • 16.6.3. Products & Services
  • 16.6.4. Financials (In case of listed companies)
  • 16.6.5. Recent Developments
  • 16.6.6. SWOT Analysis
• 16.7. Eli Lilly and Company
  • 16.7.1. Business Overview
  • 16.7.2. Company Snapshot
  • 16.7.3. Products & Services
  • 16.7.4. Financials (In case of listed companies)
  • 16.7.5. Recent Developments
  • 16.7.6. SWOT Analysis
• 16.8. Merck & Co, Inc.
  • 16.8.1. Business Overview
  • 16.8.2. Company Snapshot
  • 16.8.3. Products & Services
  • 16.8.4. Financials (In case of listed companies)
  • 16.8.5. Recent Developments
  • 16.8.6. SWOT Analysis
• 16.9. Pfizer, Inc.
  • 16.9.1. Business Overview
  • 16.9.2. Company Snapshot
  • 16.9.3. Products & Services
  • 16.9.4. Financials (In case of listed companies)
  • 16.9.5. Recent Developments
  • 16.9.6. SWOT Analysis
• 16.10.AstraZeneca Plc.
  • 16.10.1. Business Overview
  • 16.10.2. Company Snapshot
  • 16.10.3. Products & Services
  • 16.10.4. Financials (In case of listed companies)
  • 16.10.5. Recent Developments
  • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer